Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONTRIL vs TENUATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.
FDA-approved for management of obesity as a short-term adjunct (few weeks) in a regimen of weight reduction based on caloric restriction, exercise, and behavior modification. Off-label uses are not well documented due to limited evidence.
FDA-approved: short-term (up to 12 weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with exogenous obesity.,Off-label: long-term management of obesity (not FDA-approved for extended use).
BONTRIL 50 mg orally once daily, with or without food.
25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
4-6 hours (terminal); clinical context: short half-life supports multiple daily dosing
Phendimetrazine is extensively metabolized in the liver, primarily via N-demethylation to its active metabolite phenmetrazine. Minor pathways include hydroxylation and conjugation. Cytochrome P450 enzymes are involved, though specific isoforms are not fully characterized.
Extensively metabolized in the liver via N-dealkylation to active metabolites (ethylaminopropiophenone and diethylaminopropiophenone). Enzymes involved include CYP3A4 and CYP2D6.
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
Renal (90% as metabolites, ~10% unchanged); minor biliary/fecal (<10%)
85-90% bound to albumin and alpha-1-acid glycoprotein.
~92% (primarily albumin)
3-5 L/kg; indicates extensive tissue distribution.
~4 L/kg (extensive tissue distribution, including CNS)
Oral: 70-80% (first-pass metabolism); IV: 100%.
Oral: ~60-70% (first-pass metabolism)
GFR >60 m L/min: no adjustment. GFR 30-60 m L/min: reduce dose to 25 mg once daily. GFR <30 m L/min: use is not recommended.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 25 mg once daily. Child-Pugh Class C: use is contraindicated.
Contraindicated in Child-Pugh Class C; use with caution in Class A and B, consider dose reduction.
Weight-based: 1 mg/kg orally once daily, with a maximum of 50 mg. Not recommended for children weighing less than 10 kg.
Not recommended for children under 16 years of age.
Start at 25 mg orally once daily; may increase to 50 mg after 2 weeks if tolerated and renal function is adequate (Cr Cl >60 m L/min).
Initial dose at 12.5 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects.
None
There is no FDA boxed warning for Tenuate.
Risk of abuse, dependence, and tolerance; monitor for signs of addiction.,May cause serious cardiovascular events including pulmonary hypertension and valvular heart disease, especially with long-term use.,May impair ability to drive or operate machinery due to dizziness or blurred vision.,Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse.,Concomitant use with other sympathomimetics or MAO inhibitors can cause hypertensive crisis.,Not recommended for use in patients with a history of epilepsy or those taking other anorectic agents.
Primary pulmonary hypertension: rare but serious condition associated with use.,Cardiac valvulopathy: risk increases with prolonged use or combination with other serotonergic drugs.,Tachyphylaxis: tolerance to anorectic effects may develop within a few weeks.,Psychiatric effects: may exacerbate psychiatric disorders, particularly in patients with history of substance abuse.,Seizures: risk increased in patients with epilepsy or history of seizures.
Known hypersensitivity to phendimetrazine or any component of the formulation.,History of cardiovascular disease including coronary artery disease, arrhythmias, or congestive heart failure.,Hypertension (moderate to severe).,Hyperthyroidism.,Glaucoma.,History of drug abuse or alcoholism.,Concurrent use of monoamine oxidase inhibitors or within 14 days of such use.,Pregnancy and breastfeeding.,Agitated states.,History of seizure disorders.
Hypersensitivity to diethylpropion or other sympathomimetic amines.,Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma.,History of drug abuse, agitated states.,Concurrent use (or within 14 days of discontinuing) MAO inhibitors (hypertensive crisis risk).
Avoid high-fat meals as they may delay absorption of oral formulations. No specific food-drug interactions known; however, anticholinergic effects may be exacerbated by alcohol.
Avoid caffeine and other stimulants (e.g., in coffee, tea, cola, energy drinks) as they may increase cardiovascular side effects. Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if also taking MAOIs, but this is relevant only if transitioning therapy. No specific food restrictions otherwise, but a reduced-calorie diet is essential for efficacy.
BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal respiratory depression if used near term.
First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal growth and neonatal withdrawal symptoms (tremors, hypertonia, feeding difficulties). Avoid use unless clearly needed.
No data available on excretion into human breast milk. M/P ratio unknown. Due to potential for serious adverse effects in nursing infants, breastfeeding is contraindicated during BONTRIL therapy.
Excreted in human milk; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., irritability, poor weight gain). Use caution; decision to discontinue nursing or drug based on importance to mother.
No dose adjustment required for pregnancy. However, due to teratogenicity, BONTRIL should be discontinued before conception or as soon as pregnancy is diagnosed.
No specific pharmacokinetic data; however, pregnancy may alter metabolism. Start with lowest effective dose (25 mg BID) and monitor clinical response. Avoid sustained-release formulations due to altered GI transit.
BONTRIL (hyoscyamine) is an anticholinergic used for GI spasms; avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. Onset of action is 2-3 minutes IV; monitor for heat stroke in high ambient temperatures due to decreased sweating.
Tenuate (diethylpropion) is a sympathomimetic amine anorectic indicated for short-term (8-12 weeks) adjunct in obesity management. Avoid in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, or glaucoma. Monitor blood pressure and heart rate regularly. Tolerance may develop; discontinue if tolerance occurs. Contraindicated with MAOIs or within 14 days of their use. May impair ability to drive or operate machinery.
Do not drive or operate machinery until you know how this medication affects you, as it may cause dizziness or blurred vision.,Avoid alcohol and other CNS depressants as they may increase sedation.,Report immediately if you experience eye pain, difficulty urinating, or rapid heartbeat.,Use caution in hot weather; this drug reduces sweating and increases risk of heat stroke.
Take exactly as prescribed; do not increase dose or duration.,May cause dizziness or blurred vision; avoid driving if affected.,Inform your doctor if you have heart disease, high blood pressure, or thyroid problems.,Avoid alcohol and other CNS stimulants while taking this medication.,Report any chest pain, palpitations, or severe headache immediately.,Do not take with other appetite suppressants without consulting your doctor.,This medication is only for short-term use; combine with diet and exercise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONTRIL vs TENUATE, answered by our medical review team.
BONTRIL is a Sympathomimetic Anorectic that works by Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.. TENUATE is a Sympathomimetic anorectic that works by Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONTRIL and TENUATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONTRIL is: BONTRIL 50 mg orally once daily, with or without food.. The standard adult dose of TENUATE is: 25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONTRIL and TENUATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONTRIL is classified as Category C. BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft p. TENUATE is classified as Category C. First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.